Analysis of the main efficacy and therapeutic effects of larotinib/larlotinib

Larotrectinib is a highly selective TRK inhibitor, its main efficacy is the precise treatment of solid tumors caused by NTRK gene fusion mutations. NTRK (neurotrophic tyrosine kinase) gene fusion is a rare but common genetic mutation that occurs in many cancer types, resulting in sustained activation of the TRK protein, thereby abnormally stimulating the growth and spread of cancer cells. Larotrectinib inhibits the activity of three TRK receptors, TRKA, TRKB and TRKC, and blocks abnormal signaling pathways, thereby effectively curbing tumor growth and metastasis.

Clinical trial data show that larotrectinib exhibits significant anti-tumor activity in multiple NTRK fusion-positive cancer types. In phase I/II clinical trials, the drug achieved an objective response rate (ORR) of up to 75% in pediatric and adult patients, with some patients even achieving complete response (CR). This remarkable efficacy makes it the world's first approved "broad-spectrum" anti-cancer targeted drug, that is, no matter what tissue or organ the cancer originates from, as long as there is NTRK gene fusion, it may respond to larotrectinib. The drug is suitable for a variety of solid tumors, including lung cancer, thyroid cancer, colorectal cancer, breast cancer, sarcoma, neuroblastoma, etc. It provides a new precision treatment option especially for patients who are ineffective or resistant to other treatments.

In addition to its significant anti-tumor effects, larotrectinib also performed well in terms of safety and tolerability. Unlike traditional chemotherapy or some pan-targeted drugs, it has less impact on normal cells, so the adverse reactions are relatively mild, mainly including fatigue, mild liver function abnormalities, dizziness, nausea, etc., and can be tolerated by most patients. This makes larotrectinib an important treatment option for patients with advanced or relapsed and refractory tumors, improving the patient's quality of life.

Reference materials:https://www.vitrakvi.com/